[P12] 代謝・神経変性疾患

[P12-108] Interim results from RESPOND study: nusinersen in children with SMA previously treated with onasemnogene abeparvovec

^○Taihei Homma¹, Riccardo Masson², Crystal Proud³, Julie A. Parsons⁴, Nancy L. Kuntz⁵, Richard S. Finkel⁶, Foster Richard⁷, Li Wenjing⁸, Youn Bora⁸, Angela D. Paradis⁸, Rane Shweta⁸, Angela D. Paradis¹⁰, Rane Shweta¹⁰ (1.Biogen Japan Ltd, 2.Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy, 3.Children's Hospital of The King's Daughters, Norfolk, VA, USA, 4.Children's Hospital Colorado, Aurora, CO, USA, 5.Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, USA, 6.Children's Hospital of Philadelphia, Philadelphia, PA, USA, 7.Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA, 8.Massachusetts General Hospital, Boston, MA, USA, 9.Biogen, Maidenhead, Berkshire, UK, 10.Biogen, Cambridge, MA, USA)